January 18, 2024 11:03 AM EST
News Briefing

Virid­i­an’s $150M of­fer­ing; Sur­rozen scraps IBD drug can­di­date; As­sem­bly ends deal with In­di­ana Uni­ver­si­ty

Katherine Lewin

News Reporter

Jaimy Lee

Deputy Editor

Lei Lei Wu

News Reporter

Plus, news about Vor Bio, Vaxxin­i­ty, Im­mat­ics and Cer­tis On­col­o­gy:

Virid­i­an Ther­a­peu­tics’ $150M pub­lic of­fer­ing: The Waltham, MA-based biotech is sell­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

A service from the Financial Times